Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 4 of 4

TitleReference numberPublishedLast updated
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitisES35
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritisES29
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)ESNM64

Results per page

  1. 10
  2. 25
  3. 50
  4. All